NeuroVive Pharmaceutical AB Valor da empresa
Qual é o Valor da empresa de NeuroVive Pharmaceutical AB?
O Valor da empresa de NeuroVive Pharmaceutical AB é $10.23M
Qual é a definição de Valor da empresa?
O valor da empresa é uma medida do valor total de mercado de uma empresa. É calculado como capitalização de mercado com dívida, participação minoritária e ações preferenciais menos o total de caixa e equivalentes de caixa.
It is a sum of claims by all claimants including creditors (secured and unsecured) and shareholders (preferred and common). Enterprise value is one of the fundamental metrics used in business valuation, financial modeling, accounting, portfolio analysis, and risk analysis. Enterprise value is more comprehensive than market capitalization, which only reflects common equity and is considered more representative of a company’s value. Enterprise value reflects the opportunistic nature of business and may change substantially over time because of both external and internal conditions.
Enterprise value can be negative if the company holds abnormally high amounts of cash that is not reflected in the market value of the stock and total capitalization. Cash is subtracted in the calculation because it reduces the net cost to a potential purchaser. The effect applies whether the cash is used to issue dividends or to pay down debt. Value of minority interest is added because it reflects the claim on assets consolidated into the firm in question. Value of associate companies is subtracted because it reflects the claim on assets consolidated into other firms. EV should also include such special components as unfunded pension liabilities, employee stock options, environmental provisions, abandonment provisions, and so on, since they also reflect claims on the company.
Valor da empresa de empresas na Setor Health Care em OTC em comparação com NeuroVive Pharmaceutical AB
O que NeuroVive Pharmaceutical AB faz?
Abliva AB (publ), a pharmaceutical company, engages in the research and development of mitochondrial medicine. The company is developing KL1333 that is in Phase I clinical trials for the chronic treatment of primary mitochondrial diseases; NV354, which is in the preparation for clinical trials for the treatment of primary mitochondrial diseases with Complex I deficiency; and NeuroSTAT for traumatic brain injury. It has collaboration agreements with Isomerase, Yungjin Pharm, University of Pennsylvania, Children's Hospital of Philadelphia, Patheon, and Oroboros Instruments. The company was formerly known as NeuroVive Pharmaceutical AB (publ) and changed its name to Abliva AB (publ) in May 2020. Abliva AB (publ) was incorporated in 2000 and is headquartered in Lund, Sweden.
Empresas com valor da empresa semelhantes a NeuroVive Pharmaceutical AB
- Fuel Tech Inc tem Valor da empresa de $10.20M
- Clifton Mining Co tem Valor da empresa de $10.21M
- Mosaic ImmunoEngineering tem Valor da empresa de $10.22M
- Pembridge Resources plc tem Valor da empresa de $10.23M
- Sky Metals tem Valor da empresa de $10.23M
- Aurora Minerals tem Valor da empresa de $10.23M
- NeuroVive Pharmaceutical AB tem Valor da empresa de $10.23M
- I Synergy tem Valor da empresa de $10.24M
- Valhalla Metals tem Valor da empresa de $10.24M
- Ocean Grown Abalone tem Valor da empresa de $10.24M
- Peeks Social tem Valor da empresa de $10.24M
- Diagnos tem Valor da empresa de $10.25M
- Inventis tem Valor da empresa de $10.25M